GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LY2963016

Company
Eli Lilly and Company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01374178

    A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

    Not yet reported Eli Lilly and Company 16 participants Est. completion 2011-07 1 site Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01421147

    A Study in Adults With Type 1 Diabetes

    Not yet reported Eli Lilly and Company 536 participants Est. completion 2013-04 52 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT01421459

    A Study in Adults With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 759 participants Est. completion 2012-09 62 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01476345

    A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants

    Not yet reported Eli Lilly and Company 80 participants Est. completion 2012-07 1 site Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01600950

    A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 20 participants Est. completion 2012-07 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT01634165

    A Study of LY2963016 in Healthy Participants

    Not yet reported Eli Lilly and Company 24 participants Est. completion 2012-09 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01688635

    A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants

    Not yet reported Eli Lilly and Company 91 participants Est. completion 2013-02 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02302716

    A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 493 participants Est. completion 2016-07 44 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02955953

    A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants

    Not yet reported Eli Lilly and Company 127 participants Est. completion 2017-01-04 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03338010

    A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 536 participants Est. completion 2020-03-18 32 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03338023

    A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 272 participants Est. completion 2020-03-05 20 sites Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT03555305

    A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

    Not yet reported Eli Lilly and Company 58 participants Est. completion 2019-11-04 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04153981

    A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

    Not yet reported Eli Lilly and Company 304 participants Est. completion 2021-07-30 11 sites
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT04864977

    A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company Est. completion 2022-06-06 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.